155 related articles for article (PubMed ID: 34915838)
21. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
22. Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes.
Xie D; Wang Q; Huang W; Zhao L
Eur J Clin Pharmacol; 2023 Oct; 79(10):1291-1301. PubMed ID: 37493797
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
25. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review.
Reghunath SR; Rashid M; Chandran VP; Thunga G; Shivashankar KN; Acharya LD
Diabetes Metab Syndr; 2023 Jul; 17(7):102790. PubMed ID: 37329838
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin.
Fernandes G; Matos JE; Jaffe DH; Beyer G; Yang L; Iglay K; Gantz I; Rajpathak S
Curr Med Res Opin; 2020 Mar; 36(3):377-386. PubMed ID: 31771370
[No Abstract] [Full Text] [Related]
27. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
Sugiyama S; Yamamoto T; Aoyama Y
J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl peptidase-4 inhibitor-related renal disease.
Suenaga A; Sawa N; Oba Y; Ikuma D; Sekine A; Hasegawa E; Mizuno H; Suwabe T; Ikeda S; Tsujimoto T; Kono K; Shintani-Domoto Y; Kinowaki K; Ohashi K; Miyazono M; Yamaguchi Y; Ubara Y
J Diabetes Complications; 2023 Oct; 37(10):108590. PubMed ID: 37678056
[TBL] [Abstract][Full Text] [Related]
29. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
Kappel BA; Marx N; Federici M
Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
[TBL] [Abstract][Full Text] [Related]
30. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
[TBL] [Abstract][Full Text] [Related]
31. No increased heart failure risk is reported with DPP-4 inhibitors.
Wise J
BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
[No Abstract] [Full Text] [Related]
32. Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.
Patel KV; Sarraju A; Neeland IJ; McGuire DK
Curr Cardiol Rep; 2020 Aug; 22(10):105. PubMed ID: 32770420
[TBL] [Abstract][Full Text] [Related]
33. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
[TBL] [Abstract][Full Text] [Related]
34. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Scheen AJ
Diabetes Metab; 2021 Mar; 47(2):101213. PubMed ID: 33249199
[TBL] [Abstract][Full Text] [Related]
35. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zhang F; Xu S; Tang L; Pan X; Tong N
Front Endocrinol (Lausanne); 2020; 11():288. PubMed ID: 32582019
[No Abstract] [Full Text] [Related]
36. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
37. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
38. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
39. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
40. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V
Diabetes Obes Metab; 2021 Mar; 23(3):763-773. PubMed ID: 33269512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
